Subject category:
Finance, Accounting and Control
Published by:
Thunderbird School of Global Management
Abstract
On April 21, 2014 two companies, Valeant Pharmaceuticals and Pershing Square, announced an unsolicited merger offer for Allergan Pharmaceuticals. The unsolicited offer quickly turned into a hostile acquisition. The following months saw a raging public debate over the future control of Allergan and its primary product, Botox, as well as the business strategies and philosophies of the two offering firms and their CEOs.
Location:
Industry:
Subject category:
Finance, Accounting and Control
Published by:
Thunderbird School of Global Management
Length: 5 pages
Data source: Published sources
About
Abstract
On April 21, 2014 two companies, Valeant Pharmaceuticals and Pershing Square, announced an unsolicited merger offer for Allergan Pharmaceuticals. The unsolicited offer quickly turned into a hostile acquisition. The following months saw a raging public debate over the future control of Allergan and its primary product, Botox, as well as the business strategies and philosophies of the two offering firms and their CEOs.
Settings
Location:
Industry:
Related
Subject category:
Finance, Accounting and Control
Published by:
Thunderbird School of Global Management
Length: 5 pages
Data source: Published sources